Immuron (IMRN) Return on Capital Employed (2019 - 2024)
Immuron (IMRN) posted quarterly Return on Capital Employed of 56844044230936.93% for Q4 2024, up 5684404439541870.0% year-on-year from N/an in Q1 2024, and up 34559481317.57% on a QoQ basis from 164481.76% in Q4 2023.
Immuron (IMRN) Return on Capital Employed (2019 - 2024) Analysis & Trends
Immuron (IMRN) has reported Return on Capital Employed for 5 consecutive years, with 56844044230936.93% the latest figure, recorded in Q4 2024.
- Quarterly Return on Capital Employed rose 5684404439541870.0% year-over-year to 56844044230936.93% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 56844044230936.93% (up 5684404439541870.0% YoY) and the FY2025 annual result came in at 166.56%, down 13627.0% from the prior year.
- Return on Capital Employed improved to 56844044230936.93% in Q4 2024 per IMRN's latest filing, from 164481.76% in the prior quarter.
- Over the last five years, Return on Capital Employed for IMRN reached as high as 56844044230936.93% in Q4 2024 and fell as low as 316943.11% in Q4 2021.
- A 4-year average of 11368808677318.68% and a median of 170070.46% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed surged 558870 bps — and 2024, when it jumped 2000000000 bps.
- Year by year, Return on Capital Employed stood at 316943.11% in 2021, then jumped by 46 bps to 170070.46% in 2022, then rose by 3 bps to 164481.76% in 2023, then jumped by 2000000000 bps to 56844044230936.93% in 2024.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 56844044230936.93%, 164481.76%, and 192848.19% for Q4 2024, Q4 2023, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Immuron | 270.20 Mn | 258.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 56,844,044,230,936.93% |
| Dec 31, 2023 | -164,481.76% |
| Jun 30, 2023 | -192,848.19% |
| Dec 31, 2022 | -170,070.46% |
| Dec 31, 2021 | -316,943.11% |
| Dec 31, 2019 | -352,613.62% |